Expert Perspectives on the Outcomes of COCOON and Impact on Standard of Care
October 1st 2025Panelists discuss how the COCOON regimen's tolerability and effectiveness in reducing dose interruptions will improve patient experience and outcomes, requiring substantial nursing support and patient education for successful implementation in clinical practice.
Key Results From the COCOON Study for EGFRm NSCLC Patients
October 1st 2025Panelists discuss how the COCOON study demonstrated a significant reduction in grade 2 or higher dermatologic adverse events from 73% to 41%, with particularly notable improvements in face, body, and scalp rashes while maintaining comparable response rates.
Expert Perspectives on the Design and Population of the COCOON Study
September 24th 2025Panelists discuss how the COCOON trial design represents a straightforward approach using standard practice medications, though implementation challenges include patient compliance with the complex 4-drug regimen requiring significant education and support staff involvement.
The COCOON Study Design and Baseline Characteristics
September 24th 2025Panelists discuss how the COCOON study randomly assigned patients to either standard care or proactive dermatologic management using prophylactic antibiotics, topical treatments, skin moisturization, and anticoagulation to reduce grade 2 or higher dermatologic adverse events.
Provider Perspectives on Managing EGFRm NSCLC
September 17th 2025Panelists discuss how dermatologic adverse events with EGFR inhibitors are more severe than previously seen with third-generation tyrosine kinase inhibitors, requiring reactive management strategies including topical steroids, antibiotics, and dermatologic consultations that are often difficult to obtain.